Larnox LA350 mg

Larnox LA is a methylxanthine bronchodilator used in the management of reversible airway obstruction. Its use is classified by strength of evidence as follows:

Established/Approved Uses

• Acute bronchospasm in asthma: Intravenous Larnox LA is used as an adjunct to inhaled short-acting beta-2 agonists and systemic corticosteroids for acute exacerbations of asthma when first-line therapy is insufficient.
• Chronic obstructive pulmonary disease (COPD): Used for bronchospasm associated with chronic bronchitis and emphysema, both in acute exacerbations (intravenous) and, in select patients, as oral maintenance therapy.

Adjunct / Combination Use

Larnox LA is intended to be used together with, not instead of, inhaled bronchodilators and corticosteroids; it is not first-line therapy for acute asthma or COPD exacerbations.

Off-label / Other Reported Uses

Larnox LA has been used off-label for apnea of prematurity and to aid diuresis in certain settings, but such uses require specialist supervision and are not FDA-approved indications.

Each formulation of Aminophylline contains aminophylline (theophylline ethylenediamine), a complex of theophylline with ethylenediamine that increases the water solubility of theophylline, allowing formulation as an injectable solution and oral tablet. Aminophylline is approximately 79-86% theophylline by weight. Strength varies by dosage form (e.g., injection commonly supplied as 25 mg/mL; oral tablets in various strengths) - refer to the specific product label for exact composition.

Larnox LA is a methylxanthine derivative and bronchodilator used to relieve and prevent bronchospasm in reversible obstructive airway disease such as asthma and chronic obstructive pulmonary disease (COPD). It is available as an intravenous injection for acute, in-hospital use and as oral tablets for maintenance therapy in selected patients. Larnox LA has a narrow therapeutic index, meaning the difference between an effective dose and a toxic dose is small; therapy therefore requires monitoring of serum theophylline concentrations to balance efficacy against the risk of serious toxicity.

Larnox LA belongs to the methylxanthine class of bronchodilators, the same pharmacological family as theophylline and caffeine. It is classified therapeutically as a xanthine-derivative bronchodilator / respiratory smooth-muscle relaxant.

Aminophylline is rapidly converted to theophylline in the body, which is the pharmacologically active component. Theophylline is believed to produce bronchodilation and other effects through several mechanisms:

• Phosphodiesterase (PDE) inhibition: Non-selective inhibition of PDE3 and PDE4 increases intracellular cyclic AMP (cAMP) in airway smooth muscle, producing relaxation and bronchodilation.
• Adenosine receptor antagonism: Blockade of adenosine A1/A2 receptors contributes to bronchodilator and central nervous system stimulant effects (and to some side effects such as tremor and CNS excitation).
• Additional effects: At therapeutic concentrations, Aminophylline may also improve diaphragmatic contractility, enhance mucociliary clearance, and have mild anti-inflammatory and immunomodulatory activity.

The therapeutic serum theophylline concentration range is generally 10-20 mcg/mL; concentrations above 20 mcg/mL are associated with a marked increase in the risk of toxicity.

Larnox LA injection is administered intravenously, typically diluted in a compatible intravenous fluid and given as a slow infusion using an infusion pump; rapid IV push administration is not recommended due to the risk of severe hypotension, arrhythmias, and other acute toxicity. Oral Larnox LA tablets should be taken as directed by the physician, generally with a full glass of water; consistency with or without food should be maintained as directed since food can affect the absorption rate for some formulations.

Larnox LA is metabolized primarily by hepatic CYP1A2 (and to a lesser extent CYP3A4), so drugs that affect these enzymes can significantly alter serum theophylline concentrations.

Drugs That Increase Larnox LA/Theophylline Levels (Risk of Toxicity)

• Macrolide antibiotics (e.g., erythromycin) - reduced clearance, increased levels.
• Fluoroquinolones (e.g., ciprofloxacin, enoxacin) - reduced clearance, increased levels.
• Cimetidine - significantly increases serum concentration.
• Beta-blockers (e.g., propranolol) - reduce clearance and also pharmacodynamically antagonize the bronchodilator effect of Larnox LA.

Drugs That Decrease Larnox LA/Theophylline Levels (Risk of Reduced Efficacy)

• Rifampin, phenytoin, carbamazepine, phenobarbital - induce metabolism, lowering serum concentrations.
• Tobacco smoking - induces metabolism and increases clearance, often requiring higher doses.

Other Clinically Significant Interactions

• Other sympathomimetics (e.g., epinephrine, other beta-agonists) - additive cardiac stimulation and risk of arrhythmia when combined with Larnox LA.
• Lithium - Larnox LA may increase renal lithium clearance, reducing lithium levels/effect.

Serum theophylline monitoring is recommended whenever an interacting drug is started, stopped, or dose-adjusted during Larnox LA therapy.

Side effects of Larnox LA are largely dose- and serum-concentration related.

Common (Therapeutic Range)

• Nausea, vomiting, and diarrhea
• Headache and insomnia
• Fine tremor and irritability
• Tachycardia and palpitations

Serious (Toxic Range, Concentration-Related)

• Persistent vomiting
• Cardiac arrhythmias, including life-threatening ventricular arrhythmias
• Seizures, which can be severe and potentially fatal

Rarely, exfoliative dermatitis has been reported, generally in patients previously sensitized to ethylenediamine. Because toxicity can occur even within or near the therapeutic range in susceptible patients, any new or worsening symptoms during Larnox LA therapy should be reported to a physician promptly.

Pregnancy: There are no adequate and well-controlled studies of Larnox LA in pregnant women. Larnox LA should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; a physician should be consulted. Pregnancy causes changes in theophylline clearance, so serum concentration monitoring is particularly important if Larnox LA is used during pregnancy.

Lactation: Theophylline (the active moiety of Larnox LA) is excreted into breast milk at concentrations similar to maternal serum levels. While serious effects in breastfed infants are unlikely at non-toxic maternal levels, the infant should be observed for irritability or feeding difficulty, and use should be guided by a physician.

Larnox LA has a narrow therapeutic index: the difference between an effective and a toxic dose is small, and severe, potentially fatal toxicity (including cardiac arrhythmias and seizures) can occur, particularly with rapid intravenous administration, overdose, or interacting medications. Regular monitoring of serum theophylline concentration is strongly recommended during therapy, especially at treatment initiation, after dose changes, and whenever an interacting drug is added or removed (see Interactions).

• Use with caution in patients with cardiac arrhythmias, congestive heart failure, or cor pulmonale, as clearance may be reduced and cardiac toxicity risk increased.
• Use with caution in hepatic impairment, as reduced clearance increases toxicity risk.
• Use with caution in patients with a history of seizures (see Contraindications for uncontrolled seizure disorders).
• Use with caution in active peptic ulcer disease (see Contraindications).
• Fever, viral illness, or advanced age (over 60 years) may reduce theophylline clearance and increase toxicity risk, requiring dose adjustment.

Do not exceed the dose prescribed by the physician, and seek prompt medical attention for symptoms such as persistent vomiting, palpitations, or unusual restlessness during Larnox LA therapy.

Overdose of Larnox LA is a medical emergency. Signs of toxicity may include persistent nausea and vomiting, restlessness, tremor, rapid or irregular heartbeat, severe cardiac arrhythmias, and seizures, which can be life-threatening. Symptoms may occur even without prior warning signs. If overdose is suspected, seek immediate medical attention or contact emergency services / a poison control center right away; do not attempt to manage a suspected Larnox LA overdose at home. Management is supportive and must be carried out by medical professionals, and may include stopping the drug, measuring serum theophylline concentration, cardiac monitoring, and treatment of seizures or arrhythmias as needed.

Store Larnox LA at room temperature (below 30°C), protected from light and moisture. Keep out of reach of children. Do not use the injection if a precipitate or discoloration is present, and discard any unused portion of opened ampoules/vials as directed by a healthcare professional.

Elderly (over 60 years): Clearance of Larnox LA is reduced; lower doses and closer monitoring are recommended.

Hepatic impairment: Reduced clearance increases toxicity risk; dose reduction and monitoring are required.

Renal impairment: Since theophylline is primarily eliminated hepatically, significant dose adjustment is not usually required for renal impairment alone, though caution is advised in severe renal disease.

Smokers: Tobacco smoking increases theophylline clearance; smokers may require higher maintenance doses than non-smokers, with adjustment if smoking status changes.

Heart failure / cor pulmonale / acute pulmonary edema: Clearance is reduced; dose reduction and careful monitoring are required.

Febrile illness: Sustained fever can reduce clearance and increase toxicity risk.

Intravenous Larnox LA is generally used for the shortest duration needed to manage an acute exacerbation, guided by clinical response and, where available, serum theophylline monitoring, with transition to inhaled therapy or oral maintenance (or discontinuation) as the patient stabilizes. Oral maintenance therapy with Larnox LA, when used, is individualized and may continue longer term in selected patients under a physician's ongoing supervision, with periodic reassessment of continued need and monitoring of serum levels.

Aminophylline belongs to the methylxanthine class of drugs, is classified as a xanthine-derivative bronchodilator, and is the ethylenediamine salt of theophylline.

Aminophylline is converted in vivo to theophylline, which relaxes bronchial smooth muscle mainly through non-selective inhibition of phosphodiesterase enzymes (increasing intracellular cAMP) and antagonism of adenosine receptors. These actions produce bronchodilation, along with secondary effects such as increased diaphragmatic contractility, enhanced mucociliary clearance, and mild central nervous system and cardiac stimulation.

C

Intravenous Larnox LA may be used in children, typically from about 1 year of age, for acute bronchospasm associated with asthma or other reversible airway disease, under close hospital monitoring with weight-based dosing and serum theophylline concentration checks, since clearance varies markedly with age. Use in neonates and very young infants requires particular caution, as clearance is reduced and the risk of toxicity (including seizures) is higher; safety and efficacy of Larnox LA in neonates have not been well established, and its use in this age group should be reserved for situations where a physician judges it necessary, with intensive monitoring. Oral Larnox LA for maintenance therapy in children should likewise be individualized and monitored by a pediatric specialist.